United StatesHealth

Immuron (NASDAQ:IMRN) achieved record first-half sales for its lead commercial product, Travelan®, reporting a 5% year-over-year increase in global revenue to AUD$4.2 million.

Mesoblast shares were in focus Monday after the company announced positive formal feedback from the U.S. Food and Drug Administration (FDA) regarding its allogeneic cell therapy, rexlemestrocel-L.

The European Medicines Agency (EMA) has officially commenced its review of ENHERTU® (trastuzumab deruxtecan) in combination with pertuzumab, a move that could soon establish the antibody-drug conjugate (ADC) as a primary treatment for HER2-positive metastatic breast cancer in the European Union.

Harbour BioMed has transitioned from a traditional licensor to a significant shareholder in Spruce Biosciences, exercising warrants to acquire a nearly 4% stake in the California-based rare disease specialist.

Sila Realty Trust (NYSE:SILA) completed the $43.1 million acquisition of the Nobis OKC Facility on Friday, a move that underscores the REIT’s strategy of targeting market-dominant healthcare assets with high occupancy and limited competition.

ImmunityBio (NASDAQ:IBRX) announced on Friday that its mission to redefine the first-line treatment for bladder cancer is moving faster than anticipated, putting a critical regulatory filing within reach for late 2026.

Axsome Therapeutics (NASDAQ:AXSM) announced on Thursday that it has dosed the first patient in its FORWARD Phase 3 clinical trial, a pivotal step in the development of AXS-14 (esreboxetine) for the management of fibromyalgia.

Neurocrine Biosciences (NASDAQ:NBIX) presented the first head-to-head imaging data on Thursday comparing the brain-binding potency of the two leading treatments for involuntary movement disorders.

Hoth Therapeutics (NASDAQ:HOTH) announced Thursday that it has received a positive regulatory conclusion under the European Union Clinical Trials Information System (CTIS) for Part I of its HT-001 clinical program.

Beam Therapeutics (NASDAQ:BEAM) bolstered its position as a leader in the genetic medicine space on Thursday, reporting a formidable cash pile of $1.1 billion as of September 30, 2025.

Boston Scientific Corp. (NYSE:BSX) announced a definitive agreement on Thursday to acquire Penumbra (NYSE:PEN) in a cash-and-stock transaction valuing the company at $374 per share, or an enterprise value of approximately $14.5 billion.

Aurora Cannabis (NASDAQ:ACB) has entered the final stage of production trials for a new generation of cannabis cultivars designed to be naturally immune to powdery mildew, a breakthrough that could eliminate one of the industry's most expensive cultivation risks.